Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 20:12:1094400.
doi: 10.3389/fonc.2022.1094400. eCollection 2022.

The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis

Mei Lin  1 , Shupei Ma  2 , Lingling Sun  3 , Zhiqiang Qin  4
Affiliations

The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis

Mei Lin et al. Front Oncol. .

Abstract

Background: The prognostic implication of tumor-associated macrophages (TAMs) in the microenvironment of diffuse large B cell lymphoma (DLBCL) remains controversial.

Methods: A systematic and comprehensive search of relevant studies was performed in PubMed, Embase and Web of Science databases. The quality of the included studies was estimated using Newcastle-Ottawa Scale (NOS).

Results: Twenty-three studies containing a total of 2992 DLBCL patients were involved in this study. They were all high-quality studies scoring ≥ 6 points. High density of M2 TAMs in tumor microenvironment significantly associated with both advanced disease stage (OR= 1.937, 95% CI: 1.256-2.988, P = 0.003) and unfavorable overall survival (OS) (HR = 1.750, 95% CI: 1.188-2.579, P = 0.005) but not associated with poor progression free survival (PFS) (HR = 1.672, 95% CI: 0.864-3.237, P = 0.127) and international prognostic index (IPI) (OR= 1.705, 95% CI: 0.843-3.449, P = 0.138) in DLBCL patients. No significant correlation was observed between the density of CD68+ TAMs and disease stage (OR= 1.433, 95% CI: 0.656-3.130, P = 0.366), IPI (OR= 1.391, 95% CI: 0.573-3.379, P = 0.466), OS (HR=0.929, 95% CI: 0.607-1.422, P = 0.734) or PFS (HR= 0.756, 95% CI: 0.415-1.379, P = 0.362) in DLBCL patients.

Conclusion: This meta-analysis demonstrated that high density of M2 TAMs in the tumor microenvironment was a robust predictor of adverse outcome for DLBCL patients.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022343045.

Keywords: M2 TAMs; diffuse large B cell lymphoma (DLBCL); meta-analysis; prognosis; tumor-associated macrophages (TAMs).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Forest plot of total TAMs and IPI (A), disease stage (B), OS (C) and PFS (D); OR, odds ratio; hr, hazard ratio; CI, confidence interval.
Figure 3
Figure 3
Forest plot of M2 TAMs and IPI (A), disease stage (B), OS (C) and PFS (D); OR, odds ratio; hr, hazard ratio; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M, et al. . Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: Correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget (2017) 8(3):5414–25. doi: 10.18632/oncotarget.14289 - DOI - PMC - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. . The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood (2016) 127(20):2375–90. doi: 10.1182/blood-2016-01-643569 - DOI - PMC - PubMed
    1. Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW, et al. . An increase of M2 macrophages predicts poor prognosis in patients with diffuse large b-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. (2014) 55(11):2466–76. doi: 10.3109/10428194.2013.879713 - DOI - PubMed
    1. Gomez-Gelvez JC, Salama ME, Perkins SL, Leavitt M, Inamdar KV. Prognostic impact of tumor microenvironment in diffuse large B-cell lymphoma uniformly treated with r-CHOP chemotherapy. Am J Clin Pathol (2016) 145(4):514–23. doi: 10.1093/ajcp/aqw034 - DOI - PubMed
    1. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. . Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2015) 26 Suppl 5:v116–25. doi: 10.1093/annonc/mdv304 - DOI - PubMed

Publication types

LinkOut - more resources